Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity-Reference-Cited by-同舟云学术

Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

Published:2021-01-12 Issue:1 Volume:12 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Fougeroux Cyrielle^ORCID,Goksøyr Louise^ORCID,Idorn Manja^ORCID,Soroka Vladislav,Myeni Sebenzile K.,Dagil Robert^ORCID,Janitzek Christoph M.,Søgaard Max,Aves Kara-Lee^ORCID,Horsted Emma W.,Erdoğan Sayit Mahmut^ORCID,Gustavsson Tobias,Dorosz Jerzy,Clemmensen Stine,Fredsgaard Laurits^ORCID,Thrane Susan,Vidal-Calvo Elena E.^ORCID,Khalifé Paul^ORCID,Hulen Thomas M.^ORCID,Choudhary Swati,Theisen Michael,Singh Susheel K.,Garcia-Senosiain Asier,Van Oosten Linda,Pijlman Gorben^ORCID,Hierzberger Bettina^ORCID,Domeyer Tanja^ORCID,Nalewajek Blanka W.,Strøbæk Anette^ORCID,Skrzypczak Magdalena^ORCID,Andersson Laura F.,Buus Søren^ORCID,Buus Anette Stryhn,Christensen Jan Pravsgaard^ORCID,Dalebout Tim J.,Iversen Kasper,Harritshøj Lene H.,Mordmüller Benjamin^ORCID,Ullum Henrik,Reinert Line S.^ORCID,de Jongh Willem Adriaan,Kikkert Marjolein^ORCID,Paludan Søren R.^ORCID,Theander Thor G.,Nielsen Morten A.^ORCID,Salanti Ali,Sander Adam F.^ORCID

Abstract

AbstractThe rapid development of a SARS-CoV-2 vaccine is a global priority. Here, we develop two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. RBD antigens are displayed on AP205 CLPs through a split-protein Tag/Catcher, ensuring unidirectional and high-density display of RBD. Both soluble recombinant RBD and RBD displayed on CLPs bind the ACE2 receptor with nanomolar affinity. Mice are vaccinated with soluble RBD or CLP-displayed RBD, formulated in Squalene-Water-Emulsion. The RBD-CLP vaccines induce higher levels of serum anti-spike antibodies than the soluble RBD vaccines. Remarkably, one injection with our lead RBD-CLP vaccine in mice elicits virus neutralization antibody titers comparable to those found in patients that had recovered from COVID-19. Following booster vaccinations, the virus neutralization titers exceed those measured after natural infection, at serum dilutions above 1:10,000. Thus, the RBD-CLP vaccine is a highly promising candidate for preventing COVID-19.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-020-20251-8.pdf

Reference70 articles.

1. WHO/Europe | Coronavirus disease (COVID-19) outbreak - 2019-nCoV outbreak is an emergency of international concern. Available at: https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/01/2019-ncov-outbreak-is-an-emergency-of-international-concern. (Accessed: 7th July 2020)

2. Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).

3. Chen, J. et al. Receptor-binding domain of SARS-Cov spike protein: Soluble expression in E.coli, purification and functional characterization. World J. Gastroenterol. 11, 6159–6164 (2005).

4. Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444–1448 (2020).

5. Tai, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell. Mol. Immunol. 17, 613–620 (2020).

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Self-assembling amyloid-like nanostructures from SARS-CoV-2 S1, S2, RBD and N recombinant proteins;Archives of Biochemistry and Biophysics;2024-02

2. Antigen self-anchoring onto bacteriophage T5 capsid-like particles for vaccine design;npj Vaccines;2024-01-04

3. Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved Neisseria gonorrhoeae SliC antigen that blocks human lysozyme;Infection and Immunity;2023-12-12

4. Modularized viromimetic polymer nanoparticle vaccines (VPNVaxs) to elicit durable and effective humoral immune responses;National Science Review;2023-12-07

5. Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies;The Journal of Immunology;2023-11-15